Anticoagulation for Stroke Prevention in Atrial Fibrillation and Treatment of Venous Thromboembolism and Portal Vein Thrombosis in Cirrhosis

Publication Date: May 30, 2024
Last Updated: June 10, 2024

Atrial Fibrillation in Patients with Liver Disease

We recommend that patients with Child-Pugh A or B cirrhosis with AF and CHA2DS2VASc score of 2 or greater in males and 3 or greater in females be anticoagulated for stroke prevention as per current guideline recommendations in patients without cirrhosis unless otherwise contraindicated. There is inadequate evidence with respect to the benefit and risk of anticoagulation in patients with Child-Pugh C cirrhosis.
6731

Deep Vein Thrombosis/Pulmonary Embolism in Patients with Liver Disease

We recommend patients with cirrhosis and acute DVT/PE are offered treatment with anticoagulation barring a contraindication such as active bleeding, in keeping with current guideline recommendations for patients without cirrhosis.
6731

Overview

Title

Anticoagulation for Stroke Prevention in Atrial Fibrillation and Treatment of Venous Thromboembolism and Portal Vein Thrombosis in Cirrhosis

Authoring Organization